Chau Dang
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chau Dang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:22 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03377387 · Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast CancerMemorial Sloan Kettering Cancer Center · completed · Breast Cancer · principal investigator
- Ph2NCT02252887 · Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based TherapyMemorial Sloan Kettering Cancer Center · completed · Metastatic HER2-Positive Breast Cancer · principal investigator
- Ph2NCT01827163 · Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast CancerMemorial Sloan Kettering Cancer Center · completed · HER2-Positive Early Stage Breast Cancer · principal investigator
- Ph2NCT01276041 · Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast CancerMemorial Sloan Kettering Cancer Center · completed · Breast Cancer · principal investigator
- N/ANCT00617370 · Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: FeasibilityMemorial Sloan Kettering Cancer Center · completed · Breast Cancer, Adenocarcinoma of the Breast · principal investigator
- Ph2NCT00591851 · Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: FeasibilityMemorial Sloan Kettering Cancer Center · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:22 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.N Engl J Med · 2015582 citationsRCR 16.4
- 384 citationsRCR 22.8
- Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).J Clin Oncol · 2017230 citationsRCR 6.9
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.J Clin Oncol · 2019224 citationsRCR 7.6
- 198 citationsRCR 6.3
- Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease.Ann Intern Med · 1998191 citationsRCR 5.3
- 175 citationsRCR 5.4
- Benefits of off-pump bypass on neurologic and clinical morbidity: a prospective randomized trial.Ann Thorac Surg · 2003155 citationsRCR 5.2
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.Lancet Oncol · 2023152 citationsRCR 12.3
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.J Clin Oncol · 2021124 citationsRCR 6.3